Icotrokinra
Product Specifications
UNSPSC Description
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease[1].
Target Antigen
Interleukin Related; STAT
Type
Peptides
Related Pathways
Immunology/Inflammation;JAK/STAT Signaling;Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/icotrokinra.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NCCOC(C=C1)=CC=C1C[C@H](NC([C@H]2NC([C@@H](NC([C@@H](NC([C@](NC([C@@H](NC([C@H](C(C)(SSC2(C)C)C)NC(C)=O)=O)CC(N)=O)=O)([H])[C@H](O)C)=O)CC(C3=CC=C4)=CNC3=C4C)=O)CCCCNC(C)=O)=O)=O)C(N[C@@H](CC5=CC6=C(C=CC=C6)C=C5)C(NC7(CCOCC7)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N(C)CC(N)=O)=O)CC8=CN=CC=C8)=O)=O)=O)=O)=O
Molecular Weight
1898.17
References & Citations
[1]Fourie AM, et al., JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024 Jul 30;14(1):17515.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P10587/Icotrokinra-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P10587/Icotrokinra-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2763602-16-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
